Besides, Yang et al. [39] demonstrated the potential of bortezomib to suppress cell migration and invasion via FOXO3 upregulation in cholangiocarcinoma and HCC in vitro models. This evidence concerns the gene FOXO3 and cholangiocarcinoma.